Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

Original reporting
Published Sep 11, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CMNDBullishMed
01

Why it matters

The enrollment milestone reduces development risk and may attract investor interest, but actual stock movement will depend on trial data and regulatory feedback.

02

Market read

First‑in‑human enrollment for a novel AUD therapy is a material catalyst for CMND and may influence peer biotech valuations.

03

What to watch

Regulatory timeline and reimbursement landscape for psychedelic medicines remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Clearmind Medicine is a clinical‑stage company developing non‑hallucinogenic psychedelic neuroplastogens for neuropsychiatric and addiction disorders.

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

Clearmind Medicine announced the first enrollment of Alcohol Use Disorder patients in its CMND-100 trial.

Expected impact

Potential modest upside on positive interim data; downside risk if safety issues arise.

Evidence & confidence

Trial start is a key milestone for a clinical‑stage biotech; markets typically react positively to enrollment news, but impact depends on forthcoming data.

Market effects

Adds momentum to the psychedelic‑based neuroplastogen sector and may boost peer biotech valuations.

Positive signal for Canadian biotech pipeline; limited broader market effect.

Highlights growing interest in non‑hallucinogenic psychedelic therapies worldwide.

Counterpoint

If early safety signals are negative, the enrollment could be a false positive for the stock.

Key entities

  • Clearmind Medicine Inc.

    Clinical‑stage biotech developing CMND‑100 for Alcohol Use Disorder.

  • Adi Zuloff‑Shani

    CEO of Clearmind Medicine, quoted on trial progress.

Related articles

$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.